RCT: Reduced dose direct oral anticoagulants may be a safer option to vitamin K antagonists in hemodialysis patients with atrial fibrillation

Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial – Journal of the American Society of Nephrology (link to abstract – $ for full-text)

Commentary on Twitter

This study finds that patients on hemodialysis with atrial fibrillation experienced decreased cardiovascular events and major bleeding complications with direct oral anticoagulants compared with vitamin K antagonists https://t.co/6FOKkEXtfN pic.twitter.com/PD6qHaeZjT

— JASN_News (@JASN_News) March 22, 2021